Are Peptides Legal in Canada? What the Law Actually Says (2026)
Share
Are Peptides Legal in Canada? What the Law Actually Says
By the ThePeptide.ca Research Team · Written from primary sources · General information, not legal advice · Last updated July 31, 2026
Most injectable peptides are regulated as prescription drugs in Canada under the Food and Drugs Act. Without a Drug Identification Number (DIN), they are unauthorized drugs, and selling them for human use is illegal. Health Canada has stated directly that “research use only” labelling does not make a product legal or exempt it from regulatory requirements. Separately, the Canada Border Services Agency’s own memorandum states that Canadian residents may not import prescription drugs by mail or courier. Materials supplied strictly for in-vitro laboratory research are a distinct category from approved medicines — but that distinction is about intended use, not a licence.
Key takeaways
- Injectable peptides are generally prescription drugs. Under the Food and Drugs Act, a therapeutic product sold in Canada requires Health Canada authorization and a DIN. Research peptides do not have one.
- “Research use only” is not a legal exemption. Health Canada has said so explicitly. RUO describes intended use and limits what a seller may claim — it does not authorize a product.
- Canadian residents may not import prescription drugs by mail or courier. That is CBSA Memorandum D19-9-1, paragraph 45, stated without qualification.
- The “90-day supply” rule is widely misquoted. It applies to travellers physically carrying a product across the border — not to mail or courier shipments.
- Enforcement is real and recent. Health Canada seized a Canadian peptide seller’s stock in August 2025 and obtained a permanent court injunction against another in June 2026.
- Domestic fulfilment is a different question. A shipment that never crosses a border is not an import — but domestic supply is still governed by the Food and Drugs Act.
This is the most-asked question in the Canadian research peptide market, and it is almost universally answered by people selling peptides — usually without citing a single statute, regulation or government document. This page takes the opposite approach: every claim below links to the primary source, including the parts that are inconvenient for a supplier to publish.
The legal framework: what actually governs peptides in Canada
Peptides intended for human therapeutic use are regulated as drugs under the Food and Drugs Act. A drug sold in Canada must be authorized by Health Canada, which reviews it for safety, efficacy and quality and issues a Drug Identification Number (DIN) — an eight-digit number that appears on the label of every legally marketed drug product in Canada.
Research peptides do not have a DIN. Neither does retatrutide, which is investigational everywhere and not approved by any regulator. Semaglutide and tirzepatide do have DINs — but those DINs belong to specific approved products (Ozempic, Wegovy, Mounjaro), manufactured, formulated and prescribed under regulation. The DIN attaches to the product, not the molecule.
Does “research use only” create a legal exemption?
No — and Health Canada has said this directly. This is the single most important correction to make, because the opposite is implied across most of this industry.
What RUO labelling does do is define intended use and constrain what a supplier may say. A product supplied strictly for in-vitro laboratory research carries no therapeutic claims, no dosing guidance, and no representation that it is fit for human or veterinary use. That is a meaningful and legitimate distinction — laboratory reference materials are a real category and researchers genuinely need them.
But it is a statement about purpose, not a licence. If a product is in fact marketed or supplied for human use — by claim, by implication, or by the way it is presented — the RUO label does not cure that. International regulators take the same view: LegitScript, which certifies merchants for major payment processors and ad platforms, treats research-use-only framing on injectable peptides as a risk indicator rather than a defence, describing it as language that can be used to imply legal protection that does not exist.
Can I receive peptides by mail or courier in Canada?
For prescription drugs, the Canada Border Services Agency’s own memorandum says no. This is the question Canadians actually ask, and it is the one almost nobody in this market answers with a citation.
CBSA Memorandum D19-9-1, Importing Health Products for Personal Use, sets out the rules. Paragraph 45 is unqualified:
The “90-day supply” rule almost everyone misquotes
You will frequently see it claimed that Canadians may import a “90-day supply” or “single course of treatment” for personal use. That allowance is real — but it appears at paragraph 42, and it applies to travellers physically carrying a product across the border, not to shipments arriving by mail or courier. Conflating the two is the most common error in Canadian peptide content.
There is a further distinction rarely mentioned: paragraph 47 permits non-residents and visitors to import within those limits by mail or courier. The rule is different for residents and non-residents — which is why generic summaries of “Canadian import rules” are so often wrong.
| Situation | What D19-9-1 says |
|---|---|
| Canadian resident, mail or courier | May not import prescription drugs (para. 45) |
| Canadian resident, carried personally | Single course of treatment or 90-day supply, whichever is less (para. 42) |
| Non-resident or visitor, mail or courier | Permitted within the same quantity limits (para. 47) |
| Packaging | Must be in original hospital, pharmacy or retail packaging with the original label affixed (para. 43) |
What happens if a shipment is detained
CBSA detains the goods and refers them to Health Canada, which may order their disposition. This process is set out in the same memorandum and is, as far as we can find, documented nowhere else in this market — buyers are usually left with anecdotes about which port of entry is “safer.”
The sequence, per D19-9-1:
- Detention. “The CBSA may detain and refer prescription drugs to Health Canada when these conditions are not met” (para. 44).
- Referral. Health Canada advises the CBSA on admissibility (paras. 9–10).
- Disposition. Health Canada “may order disposition of goods detained by the CBSA” — in practice, the shipment does not continue to the recipient.
Health Canada has confirmed publicly that it works with the CBSA to intercept unauthorized shipments at the border, and that this activity is ongoing.
↑ Back to topWhat Health Canada has actually done
Enforcement in this sector is active, recent, and directed at sellers. Two actions in the past year are worth knowing about, because they show what conduct draws a response.
Canada Peptide — seizure, August 2025
Health Canada seized unauthorized injectable peptide drugs sold by a company operating as Canada Peptide, covering more than 50 peptide types including tirzepatide, BPC-157 and others. Health Canada stated it had not authorized any of the products seized or sold on the company’s website, and cited risks including infection and “high-risk ingredients, additives, or contaminants that may or may not be listed on the label.”
Canlab Research — permanent injunction, June 2026
The Superior Court of Québec granted Health Canada a permanent injunction on June 11, 2026 against Canlab Research, announced publicly in late July. It permanently bars the company from manufacturing, testing, distributing or selling unauthorized injectable peptides — and, notably, from advertising them “including through any website or social media platform accessible with a Canadian Internet Protocol (IP) address.”
Health Canada said the company had been selling unauthorized peptide drugs “and promoting them with many unproven health claims, despite repeated enforcement actions.” The record shows escalation over years: a consumer warning in December 2023, a Ministerial Order, a public advisory in April 2026, and finally the injunction.
Approved drug vs research material
It helps to separate the molecule from the product. Semaglutide is the active molecule in approved pharmaceutical products manufactured, formulated, tested and prescribed under strict regulation. A research-use-only peptide of the same molecule is a different thing: a laboratory reference material, without the formulation, approval, prescription or intended use of the drug product.
| Approved drug product | Research-use-only material | |
|---|---|---|
| Regulatory status | Health Canada authorized, DIN issued | Not authorized as a therapeutic; no DIN |
| Intended use | Human therapeutic use, by prescription | In-vitro and laboratory research only |
| Claims permitted | Approved indications only | None — no therapeutic claims of any kind |
| Human or animal use | As prescribed | Not for human or veterinary consumption |
| Does the label confer legality? | Authorization does | No — see above |
Why domestic fulfilment is a different question
A shipment that never crosses an international border is not an import, so the CBSA import rules above do not apply to it. That is a factual statement about logistics, not a claim about legality — and the distinction is worth stating precisely because so much Canadian peptide content blurs it.
Domestic fulfilment removes the customs question entirely: no border inspection, no detention-and-referral process, no thermal cycling in a customs facility, and lot documentation that stays within one jurisdiction. ThePeptide.ca ships from British Columbia for this reason, among others.
What domestic fulfilment does not do is change the underlying framework. The Food and Drugs Act governs supply within Canada as much as importation into it, and the Canada Peptide seizure was a domestic Canadian seller. Anyone presenting “ships from Canada” as a legal status rather than a logistics fact is overstating it — including, we would note, any supplier who does so.
↑ Back to topPurchaser responsibilities
Because these are research-use-only materials, the purchaser is responsible for handling them lawfully and appropriately. In practice that means using them only for legitimate research, in an appropriate setting, in compliance with applicable federal, provincial and institutional rules — and never for human or veterinary consumption.
If you are unsure of your obligations, consult a qualified Canadian regulatory lawyer and your institution’s compliance office before purchasing or handling research chemicals. That is the honest answer, and it is more useful than a reassuring one.
↑ Back to topFrequently asked questions
Are peptides legal in Canada?
Peptides intended for human therapeutic use are regulated as drugs under the Food and Drugs Act and require Health Canada authorization and a DIN. Without one, they are unauthorized drugs and selling them for human use is illegal. Materials supplied strictly for in-vitro laboratory research are a distinct category defined by intended use — but that is not a licence, and Health Canada has stated that “research use only” labelling does not make a product legal or exempt it from regulatory requirements.
Does “research use only” make peptides legal?
No. Health Canada has stated explicitly that RUO labelling “does not make these products legal or exempt from regulatory requirements.” RUO defines intended use and constrains what a supplier may claim. It does not authorize a product.
Can I legally receive peptides in the mail in Canada?
CBSA Memorandum D19-9-1, paragraph 45, states that Canadian residents may not import prescription drugs by mail or courier. The frequently cited “90-day supply” allowance appears at paragraph 42 and applies to travellers physically carrying a product across the border, not to mail or courier shipments. Paragraph 47 permits non-residents and visitors to import by mail within the same limits.
What happens if my package is seized at the border?
Under D19-9-1, the CBSA may detain the goods and refer them to Health Canada (paragraph 44). Health Canada advises on admissibility (paragraphs 9–10) and may order disposition of the detained goods. In practice the shipment does not reach the recipient.
Is retatrutide legal in Canada?
Retatrutide is investigational and is not approved by Health Canada, the FDA, or any other regulator. It has no DIN and may not be sold or marketed for human use in Canada. Eli Lilly has stated it plans to submit a Biologics License Application to the FDA in the first quarter of 2027, which implies any Canadian authorization would come later still.
Are these the same as Ozempic, Wegovy or Mounjaro?
No. Those are authorized, formulated, prescription pharmaceutical products with DINs. A research-use-only peptide of the same molecule is a separate laboratory reference material without the approval, formulation, prescription or intended therapeutic use of the drug product. The DIN attaches to the product, not the molecule.
Has Health Canada actually enforced against peptide sellers?
Yes. In August 2025 Health Canada seized unauthorized injectable peptide drugs sold by Canada Peptide, covering more than 50 peptide types. In June 2026 the Superior Court of Québec granted Health Canada a permanent injunction against Canlab Research, barring both sale and advertising of unauthorized injectable peptides to Canadian IP addresses.
Does buying from a Canadian supplier make it legal?
No. Domestic fulfilment means a shipment does not cross a border, so the CBSA import rules do not apply to it — that is a logistics fact, not a legal status. The Food and Drugs Act governs supply within Canada as well, and Health Canada’s August 2025 seizure involved a domestic Canadian seller.
Can I use research peptides on myself?
No. These materials are supplied for laboratory and in-vitro research only and are explicitly not for human or animal consumption. Nothing on this site is medical advice or a recommendation for personal use.
Related research resources
- FDA & Peptides in 2026: the PCAC vote, retatrutide’s Phase 3 data and what’s legal in Canada
- How to read a peptide Certificate of Analysis · Where to get peptides tested in Canada
- Buying research peptides in Canada
- Retatrutide · Tirzepatide · Semaglutide research guides
- Published lot COAs
Sources
- Canada Border Services Agency. Memorandum D19-9-1: Importing Health Products for Personal Use. cbsa-asfc.gc.ca. See in particular paragraphs 9–10, 42, 43, 44, 45 and 47.
- Health Canada. Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks. August 1, 2025. recalls-rappels.canada.ca.
- Health Canada. Health Canada obtains permanent injunction preventing Canlab Research’s illegal sale of injectable peptides in Canada. July 2026. canada.ca.
- Health Canada. Public advisory: Think twice before injecting peptides bought online. April 9, 2026. recalls-rappels.canada.ca.
- Government of Canada. Food and Drugs Act (R.S.C., 1985, c. F-27). laws-lois.justice.gc.ca.
- Eli Lilly and Company. Retatrutide Phase 3 results and planned regulatory submission. July 23, 2026. investor.lilly.com.
Changelog. July 31, 2026 — Substantially rewritten from primary sources. Added CBSA Memorandum D19-9-1 with the specific paragraphs governing mail, courier and traveller importation; corrected the widely misquoted “90-day supply” rule; added Health Canada’s explicit position that research-use-only labelling is not a legal exemption; added the detention-and-disposition process; added the Canada Peptide seizure (August 2025) and the Canlab Research permanent injunction (June 2026); added a full sources list. July 2026 — Original version published.